Dutch regulator sets out five-year strategy
This article was originally published in Scrip
Executive Summary
The Netherlands' medicines regulator, the Medicines Evaluation Board (MEB/CBG), expects to handle a decreasing share of decentralised EU marketing authorisation applications in the next five years because work will be spread more evenly across other European regulators.